Vanguard Global Advisers’s Century Therapeutics IPSC Stock Holding History
Bought
Maintained
Sold
Other funds holding IPSC
Vanguard Global Advisers's IPSC Position: Q3 2026 in Review
Vanguard Global Advisers increased its Century Therapeutics (IPSC) stake by 1.3% in Q3 2026, buying an estimated $1.23K and bringing the position to 45,218 shares worth $77.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2885.
Vanguard Global Advisers first reported a position in IPSC in Q1 2026 and has held it in 3 quarters since. The position peaked at $109K in Q2 2026. 102 funds tracked by Wall St. Rank hold IPSC as of Q3 2026.
- Vanguard Global Advisers held 45,218 shares of Century Therapeutics worth $77.3K as of Q3 2026.
- Vanguard Global Advisers bought 602 Century Therapeutics shares in Q3 2026, an estimated $1.23K.
- Century Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2885 holding.
- Vanguard Global Advisers first reported a position in Century Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Century Therapeutics position peaked at $109K in Q2 2026.
- 102 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.